HOLMES EDWARD W 4

What Happened

• Edward W. Holmes, a member of Arcturus Therapeutics' Board of Directors, was granted a 15,000-share derivative award on June 5, 2026. The grant is reported as an acquisition (code A) at an acquisition price of $0.00 (total reported value $0 on the Form 4).
• This award represents the 2026 annual board grant to Mr. Holmes and is typical board compensation rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-05; Form 4 filed: 2026-06-15 (appears to be filed after the typical 2-business-day window).
• Grant type: Derivative award (code A) for 15,000 shares; reported acquisition price $0.00.
• Vesting: Shares underlying the award vest monthly over a one-year period from the grant date (per footnote F1).
• Shares owned after transaction: not specified in the summary fields of the provided filing excerpt — refer to the full Form 4 for current holdings.
• No 10b5-1 plan, sale, tax-withholding, or cashless exercise noted in this filing.

Context

• Director awards are a common form of compensation and do not by themselves indicate insider buying or selling sentiment. Because this is a derivative/award grant with scheduled vesting, the economic interest will accrue as shares vest over the next year. The delayed filing date may be worth noting for timing/timeliness purposes.